RxDoctor Payments Data

Errold Reid, MD

Pulmonary Disease · West Nyack, NYNPI 1104230572

Payments from drug & device makers

$444in general payments, 2019–2025

Across 8 payments — averaging $55.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$184
  • W. L. Gore & Associates, Inc.$150
  • Verona Pharma, Inc.$28
  • Insmed, Inc.$22
  • Amgen$21
  • Electromed, Inc.$21
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$444 in reported general payments places this provider in the 40th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$215,275
Medicare patients
620
Services billed
1,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter155$126,054
Breo ElliptaFluticasone/Vilanterol215$99,164
Incruse ElliptaUmeclidinium Bromide44$28,107
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$26,246
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$14,375
Albuterol Sulfate HfaAlbuterol Sulfate403$11,606
Spiriva RespimatTiotropium Bromide14$10,179
Arnuity ElliptaFluticasone Furoate23$8,187
Bevespi AerosphereGlycopyrrolate/Formoterol Fum18$7,734
SymbicortBudesonide/Formoterol Fumarate19$6,047
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$5,954
Advair HfaFluticasone Propion/Salmeterol18$5,779
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$3,950
Fluticasone-VilanterolFluticasone/Vilanterol11$3,567
Wixela InhubFluticasone Propion/Salmeterol18$2,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$18$287,760473 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →